Hasna Hanchi1,2, Riadh Hammami1,3, Hélène Gingras4, Rim Kourda2, Michel G Bergeron4, Jeannette Ben Hamida2, Marc Ouellette4, Ismail Fliss1. 1. STELA Dairy Research Centre, Institute of Nutrition & Functional Foods, Université Laval, G1K 7P4 Québec, QC, Canada. 2. Unité Protéomie Fonctionnelle et Potentiel Nutraceutique de la Biodiversité de Tunisie, Institut Supérieur des Sciences Biologiques Appliquées de Tunis, Université Tunis El Manar, Tunisie. 3. Present address: Department of Soil Sciences and Agri-Food Engineering, Université Laval, Quebec, QC G1V 0A6, Canada. 4. Centre de Recherche en Infectiologie de l'Université Laval, CHUQ, Pavillon CHUL 2705 boul. Laurier, Ste-Foy, Quebec G1V 4G2, Canada.
Abstract
AIM: The aim of this study was to evaluate the efficacy of durancin 61A alone or in combination with nisin, pediocin PA-1, reuterin, microcin J25, vancomycin or tetracycline as an inhibitor of resistant clinical pathogens and to shed light on its mode of action. RESULTS: Durancin and reuterin were effective inhibitors of Clostridium difficile, vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus. The combination of durancin and reuterin was highly synergistic against C. difficile (fractional inhibitory concentration index = 0.2). Durancin/vancomycin combination was synergistic against S. aureus ATCC® 700699 (fractional inhibitory concentration index = 0.3). Conclusion & future perspective: Durancin 61A alone or combined with other bacteriocins or antibiotics may therefore provide a possible therapeutic option for the treatment of infections by these pathogens.
AIM: The aim of this study was to evaluate the efficacy of durancin 61A alone or in combination with nisin, pediocin PA-1, reuterin, microcin J25, vancomycin or tetracycline as an inhibitor of resistant clinical pathogens and to shed light on its mode of action. RESULTS:Durancin and reuterin were effective inhibitors of Clostridium difficile, vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus. The combination of durancin and reuterin was highly synergistic against C. difficile (fractional inhibitory concentration index = 0.2). Durancin/vancomycin combination was synergistic against S. aureus ATCC® 700699 (fractional inhibitory concentration index = 0.3). Conclusion & future perspective: Durancin 61A alone or combined with other bacteriocins or antibiotics may therefore provide a possible therapeutic option for the treatment of infections by these pathogens.
Authors: Felipe Miceli Farias; Lúcia Martins Teixeira; Deyse Christina Vallim; Maria do Carmo de Freire Bastos; Marco Antônio Lemos Miguel; Raquel Regina Bonelli Journal: Braz J Microbiol Date: 2021-04-26 Impact factor: 2.476
Authors: Amoe Baktash; Elisabeth M Terveer; Romy D Zwittink; Bastian V H Hornung; Jeroen Corver; Ed J Kuijper; Wiep Klaas Smits Journal: Front Microbiol Date: 2018-06-12 Impact factor: 5.640